Aurobindo Pharma is the second best gainer in the Pharma sector. Know why
Advertisement
Advertisement
Advertisement
Aurobindo Pharma Ltd., a mid-sized drugs major, was the second best gainer in the pharma sector on news that one of its medicines had won approval from the US regulator to enable it to begin sales in the world's largest generics market. Aurobindo Pharma, based in Hyderabad, said it had got the final approval from the US Food & Drug Administration to manufacture and market Raloxifene Hydrochloride Tablets in the 60 mg category. Aurobindo said its drug was the equivalent of Eli Lily's Evista Tablets and that the estimated size for this medicine in the United States was $404 million in the year to June 2015.
As a consequence, Aurobindo gained 15 rupees, or 2 percent, to 779.25 rupees on the National Stock Exchange, where 7 lakh shares were traded versus the 5-day average of 31 lakh shares.
Aurobindo has seen is market capitalisation slip 5 percent in the past one year to 44,000 crore rupees. The stock, a favourite of both investors and traders, is trading 7.9 times its book value of 96 rupees. The company has reported a 27.5 percent compounded rise in its sales over the past five years, mainly on account of higher exports.
Image credit: Indiatimes
Advertisement
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- 2 states where home prices are falling because there are too many houses and not enough buyers
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- Markets rebound in early trade amid global rally, buying in ICICI Bank and Reliance
- Women in Leadership
- Rupee declines 5 paise to 83.43 against US dollar in early trade
- Election Commission issues notification for sixth phase of Lok Sabha polls
- 6 Coffee recipes you should try this summer